Stock Analysis

Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around

JSE:DCP
Source: Shutterstock

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So when we looked at Dis-Chem Pharmacies (JSE:DCP), they do have a high ROCE, but we weren't exactly elated from how returns are trending.

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Dis-Chem Pharmacies:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.22 = R1.7b ÷ (R17b - R9.0b) (Based on the trailing twelve months to August 2023).

So, Dis-Chem Pharmacies has an ROCE of 22%. In absolute terms that's a great return and it's even better than the Consumer Retailing industry average of 17%.

See our latest analysis for Dis-Chem Pharmacies

roce
JSE:DCP Return on Capital Employed April 17th 2024

In the above chart we have measured Dis-Chem Pharmacies' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Dis-Chem Pharmacies .

What The Trend Of ROCE Can Tell Us

On the surface, the trend of ROCE at Dis-Chem Pharmacies doesn't inspire confidence. While it's comforting that the ROCE is high, five years ago it was 39%. On the other hand, the company has been employing more capital without a corresponding improvement in sales in the last year, which could suggest these investments are longer term plays. It may take some time before the company starts to see any change in earnings from these investments.

On a side note, Dis-Chem Pharmacies' current liabilities are still rather high at 54% of total assets. This can bring about some risks because the company is basically operating with a rather large reliance on its suppliers or other sorts of short-term creditors. While it's not necessarily a bad thing, it can be beneficial if this ratio is lower.

The Bottom Line On Dis-Chem Pharmacies' ROCE

In summary, Dis-Chem Pharmacies is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. And investors may be recognizing these trends since the stock has only returned a total of 21% to shareholders over the last five years. So if you're looking for a multi-bagger, the underlying trends indicate you may have better chances elsewhere.

Dis-Chem Pharmacies does have some risks though, and we've spotted 1 warning sign for Dis-Chem Pharmacies that you might be interested in.

If you'd like to see other companies earning high returns, check out our free list of companies earning high returns with solid balance sheets here.

Valuation is complex, but we're helping make it simple.

Find out whether Dis-Chem Pharmacies is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.